FDA Drug Safety Communication: Cefepime and Risk of Seizure in Patients Not Receiving Dosage Adjustments for Kidney Impairment

Why It Matters

Improper cefepime dosing poses a preventable neurologic risk, prompting hospitals to tighten prescribing protocols and safeguard vulnerable patients.

Key Takeaways

• 59 cefepime seizures reported, 58 with renal dysfunction.
• 56% of cases occurred in patients over 65 years.
• 56 of 59 lacked proper renal dosage adjustment.
• Seizures usually reversible after stopping drug or dialysis.
• FDA revises label to emphasize renal dosing warnings.

Pulse Analysis

Cefepime remains a cornerstone cephalosporin for severe hospital‑acquired infections, prized for its broad gram‑negative coverage. Yet its renal elimination pathway makes it prone to accumulation in patients with impaired kidney function, creating a neurotoxic environment that can trigger non‑convulsive status epilepticus. Recent analyses of the FDA’s AERS database reveal a clear pattern: the majority of adverse neurologic events cluster among older adults with reduced creatinine clearance, underscoring the drug’s narrow therapeutic window when dosing is not individualized.

The data show that 56 of the 59 documented seizure cases involved dosing errors, despite clear label guidance for creatinine clearance ≤ 60 mL/min. Age‑related pharmacokinetic changes and comorbidities further amplify risk, especially in females, who comprised 69% of cases. Clinicians must therefore incorporate real‑time renal function assessments into antimicrobial stewardship protocols, adjusting infusion rates or selecting alternative agents when necessary. Prompt recognition of subtle neuro‑cognitive changes—confusion, decreased responsiveness—can prevent progression to full‑blown seizures, and immediate discontinuation or hemodialysis often reverses toxicity.

The FDA’s label revision serves as a regulatory catalyst for hospitals to reinforce dosing checks within electronic health records and pharmacy verification steps. Reporting adverse events through MedWatch remains critical for ongoing surveillance and risk mitigation. By aligning prescribing practices with updated warnings, healthcare systems can reduce avoidable neurologic complications, improve patient outcomes, and maintain confidence in cefepime’s therapeutic value.